SCHEMBL14020187

SCHEMBL14020187

CCOP(=O)(CCN1CCC(N(C)S(=O)(=O)c2ccc(Nc3nccc(Nc4ccc(F)c(F)c4)n3)cc2)CC1)OCC

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 10/20 0.40
HTR1A P08908 8/20 0.40
DRD2 P14416 8/20 0.40
HTR7 P34969 8/20 0.40
ACVR1 Q04771 1/20 0.39
APOBEC3A P31941 2/20 0.39
APOBEC3G Q9HC16 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CDK2 P24941 2/20 0.38
CDK4 P11802 1/20 0.38
CCNE1 P24864 1/20 0.38
IKBKB O14920 1/20 0.38
CHUK O15111 1/20 0.38
SYK P43405 1/20 0.36
CCR2 P41597 1/20 0.36
POLB P06746 1/20 0.36
HTR2C P28335 2/20 0.36
WEE1 P30291 1/20 0.36
ALK Q9UM73 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14020208 0.94 CDK2 (0.39) HTR2AHTR1ADRD2HTR7ACVR1
SCHEMBL14020197 0.93 HTR2A (0.47) HTR2AHTR1ADRD2HTR7ACVR1
SCHEMBL14020190 0.91 CDK2 (0.38) HTR2AHTR1ADRD2HTR7CDK2
SCHEMBL4876738 0.90 APOBEC3A (0.41) HTR2AHTR1ADRD2HTR7ACVR1
SCHEMBL14020201 0.90 CDK2 (0.38) HTR2AHTR1ADRD2HTR7CDK2
SCHEMBL14020183 0.87 HTR7 (0.43) HTR2AHTR1ADRD2HTR7CDK2
SCHEMBL4880639 0.86 CDK4 (0.42) HTR2AHTR1ADRD2HTR7ACVR1
SCHEMBL4875744 0.85 IKBKB (0.42) HTR2AHTR1ADRD2HTR7ACVR1
SCHEMBL4878709 0.85 CDK2 (0.41) HTR2AACVR1APOBEC3AAPOBEC3GL3MBTL1
SCHEMBL4876612 0.85 HTR2A (0.51) HTR2AAPOBEC3AAPOBEC3GL3MBTL1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269170-A1 Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors SANOFI-AVENTIS (FR) 2008-10-30 US disclosed
WO-2007006926-A2 NOVEL 2,4-DIANILINOPYRIMIDINE DERIVATIVES, THE PREPARATION THEREOF, THEIR USE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND, IN PARTICULAR, AS IKK INHIBITORS SANOFI-AVENTIS (FR) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269170-A1 Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors NFKBIA, IKBKB, IKBKE HTR2A 3453/4885HTR1A 3698/4885DRD2 2869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.